Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
Keywords :
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
location
Contact Email
Phone number
Website URL
Similar Companies992
Ivantis
Ivantis is developing an innovative treatment for glaucoma.
Sector
Subsector
Keywords
Location
total rounds
total raised
Equinox
Equinox is a medical technology company revolutionizing the treatment of glaucoma and other progressive eye diseases.
Sector
Subsector
Location
total rounds
total raised
EndoGastric Solutions
EndoGastric Solutions provides non-surgical GERD treatment.
Sector
Subsector
Location
total rounds
total raised
EyeYon
EyeYon Medical develops medical devices for corneal edema treatment.
Sector
Subsector
Keywords
Location
total rounds
total raised
Financials
Funding Rounds7
Number of Funding Rounds
Money Raised
Their latest funding was raised on 07.02.2013. Their latest investor Montreux Equity Partners. Their latest round Series F
Montreux Equity Partners
Montreux Equity Partners is a private investment firm focused on building leading healthcare companies of the future.
Sector
Subsector
Location
count Of Investments
count Of Exists
Versant Ventures
Versant Ventures is a healthcare investment firm that helps entrepreneurs build great companies.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
InterWest Partners
InterWest is a venture capital firm that invests in healthcare and IT companies.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
OrbiMed
OrbiMed is a healthcare-focused investment firm managing approximately $5 billion in assets.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Meritech Capital Partners
Meritech Capital provides late-stage venture capital to technology companies.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Domain Associates
Domain Associates is a venture capital firm that invests exclusively in life sciences.
Sector
Subsector
Location
count Of Investments
count Of Exists
Frazier Healthcare Partners
Frazier Healthcare Partners is a private equity firm that provides growth and venture capital to healthcare companies.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Co-Investors
Investors8
Number of lead investors
Number of investors
Montreux Equity Partners
Montreux Equity Partners is a private investment firm focused on building leading healthcare companies of the future.
Sector
Subsector
Location
count Of Investments
count Of Exists
Daniel Turner
Mr. Turner has 25 years of experience as an entrepreneur, operating manager and venture capitalist. He founded Montreux and has been a General Partner/Managing Member since 1993. Immediately prior to founding Montreux, Mr. Turner was a Principal in the Turnaround Group for Berkeley International. Previously, he was the founding Chief Financial Officer of Oclassen Pharmaceuticals, a specialty pharmaceutical company focused in dermatology, which merged with Watson Pharmaceuticals (NYSE: WPI) in 1997. Mr. Turner started his career with Price Waterhouse in the high technology group. He holds a BS from California State University, Sacramento and attended the MBA program at the Haas School of Business at the University of California, Berkeley, where he has established the Turner Fellowship. Mr. Turner is a Certified Public Accountant. Mr. Turner is a member of the board of directors of GC Aesthetics, Moksha, OREXIGEN (NASDAQ: OREX), Renal CarePartners, and Tobira Therapeutics. Mr. Turner previously served as Montreux’s representative to the board of directors of Cerexa (sold to Forest Laboratories, 2007), NovaCardia (sold to Merck, 2007), Peninsula Pharmaceuticals (sold to Johnson & Johnson, 2005). In addition to his activities at Montreux, Mr. Turner is a member of the Advisory Board of the Lester Center at the Haas School of Business at the University of California, Berkeley.
current job
organization founded
Fjord Ventures
Fjord Ventures is a venture capital firm based in Laguna Hills, California that focuses on investing in the healthcare sector.
Sector
Subsector
Keywords
Location
total rounds
total raised
count Of Investments
Olav Bergheim
Olav Bergheim has over 30 years of experience in creating and managing life science companies. He is a founder of Sonendo, Inc., in addition to several other successful life science companies including Volcano Corporation, 3F Therapeutics (acquired by Medtronic), Glaukos Corporation, Lonestar Heart Inc., Prelude Corporation and Metronom Health, Inc. Mr. Bergheim is also the founder of Fjord Ventures LLC, a life science accelerator located in Laguna Hills, California, where Sonendo was created. Mr. Bergheim was the chairman of Vessix Vascular, Inc. (acquired by Boston Scientific). Prior to starting Fjord Ventures, he spent 10 years at Domain Associates as a company creator and general partner. Prior to Domain, Mr. Bergheim spent 18 years with Baxter Healthcare at US and international locations, where he held various leadership and operating roles. Mr. Bergheim was a Corporate VP of Baxter as well as President of Baxter Germany, President of Baxter’s Cardiovascular Group (now Edwards Life Sciences) and General Manager of the Nordic area.
current job
count Of Investments
Frazier Healthcare Partners
Frazier Healthcare Partners is a private equity firm that provides growth and venture capital to healthcare companies.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Robert J. More
Robert J. More joined Frazier Healthcare Ventures in 2008 as a General Partner and is a member of the firm’s biopharmaceutical and medical device investment teams. Prior to joining Frazier Healthcare, Mr. More was a Partner with Domain Associates, LLC, having joined the firm in 1996 as a Kauffman Fellow and becoming a Partner in 2000. From 1997 to 1998, Mr. More served as the COO of Small Molecule Therapeutics, Inc., a Domain portfolio company subsequently purchased by Morphochem AG. From 1992 to 1995, Mr. More was a sales professional at Pharmacia Biotech. Prior to joining Pharmacia, Mr. More held a research position at Somatogen, Inc., a company developing a recombinant blood substitute that was subsequently bought by Baxter Healthcare. While attending business school, Mr. More worked with MedVest, an early-stage venture group in Washington, DC. Mr. More has managed successful investments in and served on the boards of ESP Pharma Inc. (acquired by Protein Design Labs, Inc.), Proxima Therapeutics, Inc. (acquired by Cytyc Corporation), Onux Medical, Inc. (acquired by C.R. Bard, Inc.), NovaCardia, Inc. (acquired by Merck & Co., Inc.), Esprit Pharma, Inc. (acquired by Allergan, Inc.) and IntraLase Corporation (acquired by Advanced Medical Optics, Inc.). He serves as an advisory board member for Montagu Newhall Associates, Okapi Venture Capital, the Medical Industry Group of the National Venture Capital Association, and the Sulpizio Family Cardiovascular Center. He is also a past founding board member of the Kauffman Fellows Program. Mr. More received his MBA from the Darden School of Business Administration at the University of Virginia and a BA from Middlebury College.
current job
count Of Investments
Acquisitions2
Avedro acquired by Glaukos
acquirer
date
type
Avedro
Avedro is a medical device and pharmaceutical company advancing the science and technology of corneal cross-linking.
Sector
Subsector
Keywords
Location
total rounds
total raised
DOSE Medical Corp. acquired by Glaukos
acquirer
date
type
price
DOSE Medical Corp.
DOSE Medical Corp. is developing micro-invasive drug delivery platforms for the treatment of retinal diseases.
Sector
Subsector
Location
People
Founders3
Olav Bergheim
Olav Bergheim has over 30 years of experience in creating and managing life science companies. He is a founder of Sonendo, Inc., in addition to several other successful life science companies including Volcano Corporation, 3F Therapeutics (acquired by Medtronic), Glaukos Corporation, Lonestar Heart Inc., Prelude Corporation and Metronom Health, Inc. Mr. Bergheim is also the founder of Fjord Ventures LLC, a life science accelerator located in Laguna Hills, California, where Sonendo was created. Mr. Bergheim was the chairman of Vessix Vascular, Inc. (acquired by Boston Scientific). Prior to starting Fjord Ventures, he spent 10 years at Domain Associates as a company creator and general partner. Prior to Domain, Mr. Bergheim spent 18 years with Baxter Healthcare at US and international locations, where he held various leadership and operating roles. Mr. Bergheim was a Corporate VP of Baxter as well as President of Baxter Germany, President of Baxter’s Cardiovascular Group (now Edwards Life Sciences) and General Manager of the Nordic area.
current job
count Of Investments
Olav Bergheim
Richard A. Hill
Richard (Rick) A. Hill, MD, is a founder of Glaukos Corporation and Orange County Glaucoma. He is an Associate Professor of Ophthalmology, Emeritus, at the University of California, Irvine, and a founding member of the Armenian EyeCare Project. Dr. Hill earned his MD from Northwestern University Medical School. He subsequently completed an internship in internal medicine at Saint Joseph Hospital, a residency in ophthalmology at Pennsylvania State University - Hershey, and a clinical fellowship in glaucoma at the University of Southern California (USC) Medical Center. He has been a board-certified Ophthalmologist since 1990. He currently holds memberships in the American Academy of Ophthalmology (AAO), American Glaucoma Society (AGS), American Medical Association (AMA), and the Association for Research in Vision and Ophthalmology (ARVO). Dr. Hill has authored scientific papers, holds numerous patents, and has been an invited lecturer and presenter at scientific meetings.
current job
organization founded
Richard A. Hill
Mory Gharib
Dr. Mory Gharib is the Founder, Chairman of the Board and Scientific Advisor at Sienza Energy. Mory Gharib is a co-founder of [Glaukos](https://www.crunchbase.com/organization/glaukos#/entity), a glaucoma treatment company that develops micro-bypass therapies to moderate the intraocular pressures. Gharib holds more than 25 U.S. patents in areas of biomedical devices and imaging technology. His research areas include diverse topics and technologies such as bio-inspired design and engineering, imaging, cardiovascular research, wind and sea, energy, carbon nanotubes, and nano-scale mechanics. Gharib received his bachelor’s degree in mechanical engineering from Tehran University in 1975. He also holds a master’s degree in aerospace and mechanical engineering from Syracuse University.
current job
organization founded
Mory Gharib
Employee Profiles13
Thomas W. Burns
President & Chief Executive Officer
Gabriella Szekely
Vice President, Research and Development, Combination Pharmaceutical Products
Michele Allegretto
Senior Vice President, Human Resources
Activity
Recent News25
The graph reveals the ratio (%) of positive news articles in a chosen time range